Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Calvo Pinilla, Eva ^a   Navasa, Nicolás ^b   Anguita, Juan ^b   Ortego, Javier ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; DNA VACCINE; MARKER VACCINE; NAKED DNA; NONSTRUCTURAL PROTEIN 1; PCDNA3 NS1 VACCINE; PCDNA3 VP2 VACCINE; PCDNA3 VP7 VACCINE; PROTEIN VP2; PROTEIN VP7; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA NS1 VACCINE; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA VP2 VACCINE; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA VP7 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOENGINEERING; BLUETONGUE ORBIVIRUS; BLUETONGUE VIRUS 1; BLUETONGUE VIRUS 4; BLUETONGUE VIRUS 8; BLUETONGUE VIRUS INFECTION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; IMMUNITY; IMMUNOSTIMULATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEROTYPE; VACCINATION; VIRUS INFECTION; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; BLUETONGUE; IMMUNOLOGY; VACCINIA VIRUS;

BLUETONGUE VIRUS; MUS; ORBIVIRUS; REOVIRIDAE; VACCINIA VIRUS ANKARA;

ANIMALS; BLUETONGUE; BLUETONGUE VIRUS; DNA, VIRAL; MICE; VACCINATION; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84859730826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034735     Document Type: Article

References (43)

1. Gibbs EP, Greiner EC, (1994) The epidemiology of bluetongue. Comp Immunol Microbiol Infect Dis 17: 207-220.
2. Savini G, Maclachlan NJ, Sanchez-Vizcaino JM, Zientara S, (2008) Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 31: 101-120.
3. Mertens PP, Brown F, Sangar DV, (1984) Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology 135: 207-217.
4. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S, (2008) Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 31: 101-120.
5. Veronesi E, Darpel KE, Hamblin C, Carpenter S, Takamatsu HH, et al. (2010) Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. Vaccine 28: 1397-1403.
6. Veronesi E, Darpel KE, Hamblin C, Carpenter S, Takamatsu HH, et al. (2009) Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. Vaccine.
7. Maan S, Maan NS, van Rijn PA, van Gennip RG, Sanders A, et al. (2010) Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains. PLoS One 5: e10323.
8. Lobato ZI, Coupar BE, Gray CP, Lunt R, Andrew ME, (1997) Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet Immunol Immunopathol 59: 293-309.
9. Perrin A, Albina E, Breard E, Sailleau C, Prome S, et al. (2007) Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25: 6774-6783.
10. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, et al. (2007) Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25: 672-678.
11. Wade-Evans AM, Romero CH, Mellor P, Takamatsu H, Anderson J, et al. (1996) Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 220: 227-231.
12. Calvo-Pinilla E, Nieto JM, Ortego J, (2010) Experimental oral infection of bluetongue virus serotype 8 in type I interferon receptor-deficient mice. J Gen Virol 91: 2821-2825.
13. Calvo-Pinilla E, Rodriguez-Calvo T, Anguita J, Sevilla N, Ortego J, (2009) Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One 4: e5171.
14. Calvo-Pinilla E, Rodriguez-Calvo T, Sevilla N, Ortego J, (2009) Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine 28: 437-445.
15. Matsuo E, Celma CC, Boyce M, Viarouge C, Sailleau C, et al. (2011) Generation of Replication-Defective Virus-Based Vaccines That Confer Full Protection in Sheep against Virulent Bluetongue Virus Challenge. J Virol 85: 10213-10221.
16. Jeggo MH, Wardley RC, Taylor WP, (1984) Role of neutralising antibody in passive immunity to bluetongue infection. Res Vet Sci 36: 81-86.
17. Takamatsu H, Jeggo MH, (1989) Cultivation of bluetongue virus-specific ovine T cells and their cross-reactivity with different serotype viruses. Immunology 66: 258-263.
18. Jeggo MH, Wardley RC, (1982) Generation of cross-reactive cytotoxic T lymphocytes following immunization of mice with various bluetongue virus types. Immunology 45: 629-635.
19. Jeggo MH, Wardley RC, Brownlie J, (1984) A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques. Immunology 52: 403-410.
20. Romito M, Du Plessis DH, Viljoen GJ, (1999) Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus. Onderstepoort J Vet Res 66: 139-144.
21. Jeggo MH, Wardley RC, Taylor WP, (1984) Clinical and serological outcome following the simultaneous inoculation of three bluetongue virus types into sheep. Res Vet Sci 37: 368-370.
22. Schwartz-Cornil I, Mertens PP, Contreras V, Hemati B, Pascale F, et al. (2008) Bluetongue virus: virology, pathogenesis and immunity. Vet Res 39: 46.
23. Janardhana V, Andrew ME, Lobato ZI, Coupar BE, (1999) The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res Vet Sci 67: 213-221.
24. Andrew M, Whiteley P, Janardhana V, Lobato Z, Gould A, et al. (1995) Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet Immunol Immunopathol 47: 311-322.
25. Umeshappa CS, Singh KP, Pandey AB, Singh RP, Nanjundappa RH, (2011) Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep. Vaccine 28: 2522-2531.
26. Stott JL, Osburn BI, (1990) Immune response to bluetongue virus infection. Curr Top Microbiol Immunol 162: 163-178.
27. Roy P, (1996) Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Intervirology 39: 62-71.
28. Eschbaumer M, Keller M, Beer M, Hoffmann B, (2011) Epizootic hemorrhagic disease virus infection of type I interferon receptor deficient mice. Vet Microbiol.
29. Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, et al. (2011) A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PLoS One 6: e16503.
30. Caporale M, Wash R, Pini A, Savini G, Franchi P, et al. (2011) Determinants of bluetongue virus virulence in murine models of disease. J Virol 85: 11479-11489.
31. Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, et al. (2007) Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 81: 8707-8721.
32. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11: 189-217.
33. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11: 189-217.
34. Hemati B, Contreras V, Urien C, Bonneau M, Takamatsu HH, et al. (2009) Bluetongue virus targets conventional dendritic cells in skin lymph. J Virol 83: 8789-8799.
35. Barratt-Boyes SM, MacLachlan NJ, (1995) Pathogenesis of bluetongue virus infection of cattle. J Am Vet Med Assoc 206: 1322-1329.
36. Hewat EA, Booth TF, Wade RH, Roy P, (1992) 3-D reconstruction of bluetongue virus tubules using cryoelectron microscopy. J Struct Biol 108: 35-48.
37. de Temmerman ML, Rejman J, Demeester J, Irvine DJ, Gander B, et al. (2011) Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 16: 569-582.
38. Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM, (2011) Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 29: 294-306.
39. Rosenberg AS, (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8: E501-507.
40. Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, et al. (2002) Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21: 108-114.
41. Roy P, Bishop DH, LeBlois H, Erasmus BJ, (1994) Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12: 805-811.
42. Perez de Diego AC, Athmaram TN, Stewart M, Rodriguez-Sanchez B, Sanchez-Vizcaino JM, et al. (2011) Characterization of Protection Afforded by a Bivalent Virus-Like Particle Vaccine against Bluetongue Virus Serotypes 1 and 4 in Sheep. PLoS One 6: e26666.
43. Toussaint JF, Sailleau C, Breard E, Zientara S, de Clercq K, (2007) Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments. J Virol Methods 140: 115-123.